期刊文献+

血清CA19-9检测对良恶性梗阻性黄疸的鉴别诊断价值 被引量:10

The Value of Differential Diagnosis by Serum CA19-9 between Benign and Malignant Jaundice
下载PDF
导出
摘要 目的探讨血清CA19-9结合总胆红素检测在梗阻性黄疸良恶性鉴别诊断中的应用价值。方法选取血清CA19-9水平高于参考值的15例良性梗阻性黄疸患者和23例恶性梗阻性黄疸患者,动态监测上述患者血清CA19-9及总胆红素水平在治疗前后的变化,并探讨二者的相关性。结果良性梗阻性黄疸患者治疗后血清CA19-9水平较治疗前显著降低,差异有统计学意义(P<0.01);恶性梗阻性黄疸患者治疗前后血清CA19-9水平差异无统计学意义(P=0.067)。治疗前及治疗后良性梗阻性黄疸患者血清CA19-9水平与血清总胆红素水平均呈正相关(r值分别为0.92和0.87,P均<0.01),而恶性梗阻性黄疸患者治疗前及治疗后二者均无相关性(r值分别为0.12和0.02,P值分别为0.64和0.83)。结论利用良性梗阻性黄疸患者治疗前后CA19-9水平变化的显著差异,同时结合CA19-9与血清总胆红素呈正相关这一特征,临床上可用CA19-9结合总胆红素检测来鉴别高表达CA19-9梗阻性黄疸的良恶性。 Objective To explore the value of differential diagnosis by serum CA19-9 combinatied with serum total bilirubin to distinguish benign and malignant obstructive jaundice.Methods 15 cases of CA19-9 above the normal of benign obstructive jaundice and 23 patients with malignant obstructive jaundice patients were monitored by the serum CA19-9 and total bilirubin before and after treatment to inuestigate the correlation of the two indexs.Results Serum CA19-9 of patients with benign obstructive jaundice significantly decreased after treatment,the difference was significant(P0.01);CA19-9 of patients with malignant obstructive jaundice was no significantly difference before and after treatment(P=0.067).There was a positive correlation between the change of CA19-9 level and serum total bilirub in patients with benign obstructive jaundice before and after treatment(r=0.92 and 0.87,P0.01).However,there was no correlation in the malignant group(r=0.12 and 0.02,P=0.64 and 0.83).Conclusion Using CA19-9 levels of benign obstructive jaundice before and after treatment in patients with a significant difference,combined with positively correlation between CA19-9 and serum total bilirubin could distinguish benign from malignant obstructive jaundice.
出处 《中国全科医学》 CAS CSCD 北大核心 2011年第12期1343-1345,共3页 Chinese General Practice
关键词 黄疸 阻塞性 CA19-9 胆红素 诊断 鉴别 Jaundice obstructive CA19-9 Bilirubin Diagnosis differential
  • 相关文献

参考文献6

  • 1Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies [ J]. Somatic Cell Genet, 1979, 5:957-971.
  • 2Peterli R, Meyer - Wyss B, Herzog U, et al. CA19 -9 has no value as a tumor marker in obstructive jaundice [ J ]. Schweiz Med Wochenschr, 1999, 129 (3): 77-79.
  • 3Kim CK, Lira SJ. Recent progress in drug delivery systems for anticancer agents [J]. Arch Pharm Res, 2002, 25 (3): 229.
  • 4GUrbilz AK, Ozel AM. Elevated carbohydrate antigen CA19 -9 levels in a patient with choledecholithiasis [ J]. Turk J Gastroenterol, 2002, 13 (4) : 213 -215.
  • 5Akdbgan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19 -9 in benign conditions: a case report and review of the litera- ture [J]. Tumori, 2001, 87 (5): 337-339.
  • 6Gareth Morris-Stiff,Mary Teli,Nicky Jardine,Malcolm CA Puntis.CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease[J].Hepatobiliary & Pancreatic Diseases International,2009,8(6):620-626. 被引量:33

二级参考文献58

  • 1Steinberg WM;Gelf R;Anderson KK.Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas,1986.
  • 2Gogas H;Lofts FJ;Evans TRJ.Are serial measurements of CA-19-9 useful in predicting response to chemotherapy in patients with imperable adenocalrcinoma of the pancreas,1998(02).
  • 3MDChristopher G. Willett BAWilliam J. Daly and MDAndrew L. Warshaw.CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. The American Journal of Surgery . 1996
  • 4Nichols JC,Gores GJ,La Russo NF,et al.Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clinic Proceedings . 1993
  • 5Patel A H,Harnois D M,K lee G G,et al.The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. The American journal of Gastroenterology . 2000
  • 6Ker C G,Chen J S,Lee K T,et al.Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. Journal of Gastroenterology . 1991
  • 7Andreas Karachristos M.D., Ph.D.,Nikolaos Scarmeas M.D., M.Sc.,John P. Hoffman M.D..CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer[J]. Journal of Gastrointestinal Surgery . 2005 (9)
  • 8Mina Waraya MD,Keishi Yamashita MD, PhD,Hiroyuki Katagiri MD, PhD,Kenichiro Ishii MD, PhD,Yoshihito Takahashi MD, PhD,Kazunori Furuta MD, PhD,Masahiko Watanabe MD, PhD, FACS.Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer[J]. Annals of Surgical Oncology . 2009 (5)
  • 9Ziske,C,Schlie,C,Gorschluter,M,Glasmacher,A,Mey,U,Strehl,J,Sauerbruch,T,Schmidt-Wolf,IG.Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. British Journal of Cancer . 2003
  • 10S. L. Ong,A. Sachdeva,G. Garcea,G. Gravante,M. S. Metcalfe,D. M. Lloyd,D. P. Berry,A. R. Dennison.Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration[J]. Digestive Diseases and Sciences . 2008 (12)

共引文献32

同被引文献87

引证文献10

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部